Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:AMLX NASDAQ:AVXL NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.96-2.0%$3.49$1.24▼$4.08$784.83M1.023.74 million shs5.95 million shsAMLXAmylyx Pharmaceuticals$10.20+2.5%$8.15$2.28▼$10.24$909.50M-0.441.25 million shs1.75 million shsAVXLAnavex Life Sciences$9.40+0.4%$10.54$4.93▼$14.44$807.40M0.83905,578 shs701,998 shsMNPRMonopar Therapeutics$44.21+13.8%$38.33$2.29▼$54.30$272.78M1.237,063 shs34,621 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-5.73%-1.66%-25.44%+112.19%AMLXAmylyx Pharmaceuticals0.00%+8.74%+30.10%+91.37%+388.04%AVXLAnavex Life Sciences0.00%-2.49%-16.22%+13.66%+67.26%MNPRMonopar Therapeutics0.00%+29.46%+10.25%+19.13%+1,711.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.96-2.0%$3.49$1.24▼$4.08$784.83M1.023.74 million shs5.95 million shsAMLXAmylyx Pharmaceuticals$10.20+2.5%$8.15$2.28▼$10.24$909.50M-0.441.25 million shs1.75 million shsAVXLAnavex Life Sciences$9.40+0.4%$10.54$4.93▼$14.44$807.40M0.83905,578 shs701,998 shsMNPRMonopar Therapeutics$44.21+13.8%$38.33$2.29▼$54.30$272.78M1.237,063 shs34,621 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-5.73%-1.66%-25.44%+112.19%AMLXAmylyx Pharmaceuticals0.00%+8.74%+30.10%+91.37%+388.04%AVXLAnavex Life Sciences0.00%-2.49%-16.22%+13.66%+67.26%MNPRMonopar Therapeutics0.00%+29.46%+10.25%+19.13%+1,711.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75128.04% UpsideAMLXAmylyx Pharmaceuticals 3.00Buy$12.2520.10% UpsideAVXLAnavex Life Sciences 3.00Buy$44.00368.09% UpsideMNPRMonopar Therapeutics 3.00Buy$69.5757.37% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, AMLX, AKBA, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/2/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$80.008/28/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.008/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.008/27/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$74.008/26/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.008/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.008/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/4/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M4.90N/AN/A($0.23) per share-12.87AMLXAmylyx Pharmaceuticals$87.37M10.41N/AN/A$2.40 per share4.25AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)AMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%N/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)Latest MNPR, AMLX, AKBA, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84AMLXAmylyx PharmaceuticalsN/A8.728.72AVXLAnavex Life SciencesN/A8.938.93MNPRMonopar TherapeuticsN/A33.9333.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AMLXAmylyx Pharmaceuticals95.84%AVXLAnavex Life Sciences31.55%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%AMLXAmylyx Pharmaceuticals12.30%AVXLAnavex Life Sciences11.40%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableMNPR, AMLX, AKBA, and AVXL HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Takes Position in Monopar Therapeutics Inc. $MNPRSeptember 6 at 4:43 AM | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at OppenheimerSeptember 5 at 9:44 AM | marketbeat.comOppenheimer Initiates Coverage of Monopar Therapeutics (MNPR) with Outperform RecommendationSeptember 4 at 7:55 PM | msn.comADAR1 Capital Management LLC Has $3.67 Million Holdings in Monopar Therapeutics Inc. $MNPRSeptember 4 at 7:41 AM | marketbeat.comRaymond James Initiates Coverage of Monopar Therapeutics (MNPR) with Strong Buy RecommendationSeptember 4 at 4:24 AM | msn.comOppenheimer starts Monopar with Outperform on ALXN1840 potentialSeptember 3, 2025 | msn.comMonopar Therapeutics initiated with an Outperform at OppenheimerSeptember 3, 2025 | msn.comMonopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual MeetingSeptember 3, 2025 | globenewswire.comMonopar Therapeutics initiated with a Strong Buy at Raymond JamesSeptember 2, 2025 | msn.comQ3 Earnings Estimate for MNPR Issued By HC WainwrightAugust 30, 2025 | marketbeat.comAnalysts Issue Forecasts for MNPR Q3 EarningsAugust 30, 2025 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Cantor FitzgeraldAugust 29, 2025 | marketbeat.comMonopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Cantor FitzgeraldAugust 29, 2025 | americanbankingnews.comAffinity Asset Advisors LLC Buys Shares of 62,000 Monopar Therapeutics Inc. $MNPRAugust 28, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at HC WainwrightAugust 28, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Now Covered by HC WainwrightAugust 27, 2025 | americanbankingnews.comMonopar Therapeutics assumed with a Buy at H.C. WainwrightAugust 26, 2025 | msn.comMonopar Therapeutics management to meet with Cantor FitzgeraldAugust 22, 2025 | msn.comWhat is Chardan Capital's Forecast for MNPR FY2025 Earnings?August 19, 2025 | marketbeat.comMNPR FY2025 EPS Lifted by Brookline Capital ManagementAugust 17, 2025 | marketbeat.comCantor Fitzgerald Analysts Cut Earnings Estimates for MNPRAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR, AMLX, AKBA, and AVXL Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.96 -0.06 (-1.99%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.98 +0.02 (+0.51%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Amylyx Pharmaceuticals NASDAQ:AMLX$10.20 +0.25 (+2.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$10.12 -0.08 (-0.78%) As of 09/5/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Anavex Life Sciences NASDAQ:AVXL$9.40 +0.04 (+0.43%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.37 -0.03 (-0.32%) As of 09/5/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Monopar Therapeutics NASDAQ:MNPR$44.21 +5.37 (+13.83%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$44.18 -0.03 (-0.07%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
